Search research articles
Contact Us
Filters
Showing results (21-30 of 290) with videos related to
Page
of 29
Sort By:
Gastroenterology
|
November 26, 2011
Adalimumab in ulcerative colitis: can pharmacodynamics be improved based on pharmacokinetics?
Edouard Louis, Julián Panés
Digestive Diseases (Basel, Switzerland)
|
June 28, 2014
Can we predict the high-risk patient?
Jose-Manuel Benitez, Edouard Louis
World Journal of Gastroenterology
|
June 3, 2010
Do clinical factors help to predict disease course in inflammatory bowel disease?
Edouard Louis, Jacques Belaiche, Catherine Reenaers
Inflammatory Bowel Diseases
|
September 26, 2008
Does the phenotype at diagnosis (e.g., fibrostenosing, inflammatory, perforating) predict the course of Crohn's disease?
Edouard Louis, Catherine Reenaers, Jacques Belaiche
Gut
|
June 20, 2014
Use of azathioprine in IBD: modern aspects of an old drug
Edouard Louis, Peter Irving, Laurent Beaugerie
Revue Medicale De Liege
|
December 14, 2023
[Iatrogenic colitis following immunotherapy : monocentric retrospective study at the University Hospital of Liège]
Fernand Weerts, Catherine Loly, Edouard Louis
World Journal of Gastroenterology
|
September 24, 2008
Are we giving biologics too much time? When should we stop treatment?
Edouard Louis, J Belaiche, C Reenaers
World Journal of Gastroenterology
|
August 10, 2012
Impact of medical therapies on inflammatory bowel disease complication rate
Catherine Reenaers, Jacques Belaiche, Edouard Louis
Journal of Crohn'S & Colitis
|
March 21, 2019
The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease
Kristian Bolin, Erik Hertervig, Edouard Louis
Therapeutic Advances in Gastroenterology
|
December 25, 2010
Current directions of biologic therapies in inflammatory bowel disease
Catherine Reenaers, Edouard Louis, Jacques Belaiche
Page
of 29
Search research articles
Search
Showing results (21-30 of 290) with videos related to
Sort By:
Page
of 29
Gastroenterology
|
November 26, 2011
Adalimumab in ulcerative colitis: can pharmacodynamics be improved based on pharmacokinetics?
Edouard Louis, Julián Panés
Digestive Diseases (Basel, Switzerland)
|
June 28, 2014
Can we predict the high-risk patient?
Jose-Manuel Benitez, Edouard Louis
World Journal of Gastroenterology
|
June 3, 2010
Do clinical factors help to predict disease course in inflammatory bowel disease?
Edouard Louis, Jacques Belaiche, Catherine Reenaers
Inflammatory Bowel Diseases
|
September 26, 2008
Does the phenotype at diagnosis (e.g., fibrostenosing, inflammatory, perforating) predict the course of Crohn's disease?
Edouard Louis, Catherine Reenaers, Jacques Belaiche
Gut
|
June 20, 2014
Use of azathioprine in IBD: modern aspects of an old drug
Edouard Louis, Peter Irving, Laurent Beaugerie
Revue Medicale De Liege
|
December 14, 2023
[Iatrogenic colitis following immunotherapy : monocentric retrospective study at the University Hospital of Liège]
Fernand Weerts, Catherine Loly, Edouard Louis
World Journal of Gastroenterology
|
September 24, 2008
Are we giving biologics too much time? When should we stop treatment?
Edouard Louis, J Belaiche, C Reenaers
World Journal of Gastroenterology
|
August 10, 2012
Impact of medical therapies on inflammatory bowel disease complication rate
Catherine Reenaers, Jacques Belaiche, Edouard Louis
Journal of Crohn'S & Colitis
|
March 21, 2019
The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease
Kristian Bolin, Erik Hertervig, Edouard Louis
Therapeutic Advances in Gastroenterology
|
December 25, 2010
Current directions of biologic therapies in inflammatory bowel disease
Catherine Reenaers, Edouard Louis, Jacques Belaiche
Page
of 29